Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2021—Sysmex introduced its TH-11 Urine Sample Decapper Unit, which is designed to be used in conjunction with the Sysmex UN-Series Automated Urinalysis Solution. The unit is intended to eliminate manual decapping work, which can reduce workplace repetitive injuries, streamline work processes, and reduce exposure to biological hazards. The TH-11 comes in desktop or wagon modules.
December 2021—Lighthouse Lab Services announced that the FDA has granted emergency use authorization for its CovidNow SARS-CoV-2 assay kit. The EUA covers use for symptomatic and asymptomatic patients with a provider’s order.
December 2021—The results of Olympus’ ongoing joint research program to create an AI-based pathology diagnostic tool were announced at the Japan Society of Digital Pathology Study annual meeting. The AI tool was able to achieve 100 percent sensitivity and 50 percent or higher specificity for all gastric biopsy pathology specimens analyzed from the six facilities participating in the study.
December 2021—Bio-Rad announced its Exact Diagnostics RP Positive Run Control for syndromic respiratory panels is now available with inactivated whole virus for SARS-CoV-2. The unassayed external quality control contains 23 respiratory analytes in one vial and is intended to monitor the performance of clinical respiratory assays. The control is a combination of whole, intact virus and bacteria that have been heated or chemically inactivated and synthetic RNA transcripts.
December 2021—LumiraDx announced that the FDA’s emergency use authorization for its SARS-CoV-2 antigen test has been expanded to include screening of asymptomatic individuals. This claim builds on its existing claim that covers use of the test in individuals suspected of having COVID-19 by their health care provider within 12 days of symptom onset. The test received EUA in August 2020.
December 2021—Microbix Biosystems has expanded its portfolio of quality assessment products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.
November 2021—Verichem Laboratories offers ready-to-use, liquid-stable clinical reference materials for microprotein testing, suitable for use with turbidimetric and colorimetric test methods. The products are intended for the calibration and calibration verification of clinical systems testing for total protein and albumin in urine and cerebral spinal fluid. The kit contains a five-level set with 15 mL of material at each level and provides 10 individual certified concentrations in an azide-free format, incorporating human protein components for optimum reactivity.
November 2021—Labcon North America, a wholly owned subsidiary of Helena Laboratories, has announced a $59.3 million contract award from the U.S. Department of Defense in coordination with the U.S. Department of Health and Human Services.
November 2021—Thermo Fisher Scientific has updated its research use only Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to include the mu strain. Laboratories can build their own panel from a menu of more than 50 verified real-time PCR assays that allows the user to identify relevant SARS-CoV-2 mutations and adapt as additional mutations and variants emerge.
November 2021—Roche launched in the CE market three molecular PCR diagnostic test panels to simultaneously detect and differentiate flu A, flu B, and respiratory syncytial virus; adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and parainfluenza 1, 2, 3, and 4. The tests can be run together or individually from a single nasopharyngeal swab specimen and run on the Cobas Omni Utility Channel for use with the Cobas 6800/8800 systems.
